Loading
InduPro Therapeutics maps which proteins sit side by side on the surface of cancer cells and designs two-armed antibody-drug conjugates that bind such a pair. Its first medicine, for lung and other squamous cancers, entered a phase 1 trial in 2026.
InduPro Therapeutics, formed in 2022 with offices in Seattle and Cambridge, Massachusetts, uses a proximity-guided discovery platform to find Tumour Associated Proximity Antigens (TAPAs), proteins that sit next to a known target on cancer cells, and builds bispecific antibody-drug conjugates against the pair. Its lead IDP-001 is a bispecific ADC against EGFR and TAPA-E1; on 12 August 2026 the company reported the first patient dosed in a phase 1 study (NCT07602842) in advanced or metastatic squamous or non-squamous non-small cell lung cancer and other squamous solid tumours. Further programmes listed include IDP-012 (EGFR x TAPA-E1 with a topoisomerase 1 inhibitor payload), IDP-004 (MET x TAPA-M1) and PD-1 bispecifics for immuno-oncology and autoimmunity. Financing comprises an USD 85 million Series A in June 2024 co-led by The Column Group and Vida Ventures and a USD 77 million Series B in August 2026 led by The Column Group, with Sanofi and Eli Lilly among new investors; Lilly also signed an oncology collaboration in January 2026.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series B · Led by The Column Group | 2026 | $77M | induprotx.com |
| Series A · Co-led by The Column Group and Vida Ventures | 2024 | $85M | biospace.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares Bispecific ADC, EGFR, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, MET, EGFR, Non-small-cell lung cancer.
Shares MET, EGFR, Non-small-cell lung cancer.
Shares MET, EGFR, Non-small-cell lung cancer.
Shares Bispecific ADC, Antibody-drug conjugate (ADC), Non-small-cell lung cancer.
Shares Bispecific ADC, EGFR, Antibody-drug conjugate (ADC), Non-small-cell lung cancer.
Shares MET, Antibody-drug conjugate (ADC), Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/